Abstract. The ADCYAP1 gene encodes an adenylate cyclase activating polypeptide 1. ADCYAP1 has been known to be involved in various biological processes. Multiple cytosine guanine dinucleotides (CpG island) are found in the ADCYAP1 promoter region. Transcriptional silencing by promoter hypermethylation is an important regulatory mechanism in tumorigenesis in many cancers. Therefore, the methylation level of the ADCYAP1 promoter was investigated in eight cervical cancer cell lines and human tissue samples with a distinctive degree of malignant transformation. While multiple CpG sites in the ADCYAP1 promoter were highly methylated in CIN III and invasive carcinoma cells as well as seven cervical cancer cell lines, they were rarely methylated in normal cells. Importantly, methylation in the ADCYAP1 promoter seems to start from CIN I, relatively early stage of multistep carcinogenesis. This fact suggest that ADCYAP1 can be used as an effective and sensitive methylation biomarker for the early diagnosis of cervical cancer. Moreover, our data imply that the level of the ADCYAP1 promoter hypermethylation is correlated with cervical cancer development. We also show that ADCYAP1 gene expression was reactivated by the treatment of a DNA methyltransferase inhibitor of 5'-aza-2'deoxycytidine and/or a histone deacetylase inhibitor of trichostain A in cervical cancer cells suggesting that hypermethylation in the ADCYAP1 promoter is responsible for the transcriptional silencing of the ADCYAP1 gene in cervical cancer cells.
Introduction
Cervical cancer is an malignant tumor of the cervix uteri or cervical area. In spite of various advanced treatments, cervical cancer still remains a fatal disease worldwide for women (1) . When infected by human papillomavirus (HPV), the cervical epithelial cells develop from premalignant cervical lesions to malignant invasive cancer via multistep processes (2) (3) (4) (5) . The multistep carcinogenesis can be classified into five groups: normal, cervical intraepithelial neoplasia I (CIN I, mild dysplasia), cervical intraepithelial neoplasia II (CIN II, moderate dysplasia), cervical intraepithelial neoplasia III (CIN III, severe dysplasia), and invasive cervical carcinoma (6, 7) . Fortunately, most cases of CIN do not develop to cervical cancer and only a small percentage of cases becomes cervical cancer if they are not well treated (7) . Moreover, this process is a relatively slow event with a long interval between infection and cancer. Therefore, the development of a diagnostic system for early detection has been considered as one of the most powerful tools in the diagnostic area. Several such diagnostic technologies (e.g., Pap smear screening or HPV testing) have been developed. However, their efficiency has been questioned for many reasons including sampling, interpretation errors, cost, and low specificity and sensitivity.
Currently, many researchers are interested in developing diagnostic tools for the early detection of various cancers using epigenetic alterations in the oncogenes and tumor suppressor genes. Representative epigenetic alteration is the hypermethylation at CpG islands of a genomic DNA (8) . DNA methylation has been considered to be very useful tool for the detection of various cancers (9) . Hypermethylation in the promoter region of potential tumor suppressor genes often leads to a repressed gene expression and therefore the loss of normal function. This epigenetic silencing is now recognized as a frequent event in the (10) (11) (12) (13) (14) (15) (16) . In other words, methylated cytosines are absent in the promoter of normal cells but are present in that of cancer cells. Accordingly, DNA methylation can be used as a powerful biomarker for the diagnosis of many cancers (17) . A number of different approaches to genome-wide identification of cancer-associated hypermethylated genes have been developed (9) . Nevertheless, at the present time only a few cervical cancer specific methylation markers have been identified. Our goal is to identify more effective and sensitive methylation biomarkers. For this purpose, we have initially focused on evaluating the value of ADCYAP1 for a new methylation-based biomarker. The ADCYAP1 gene encodes an adenylate cyclase activating polypeptide 1. This gene belongs as a member of the secretin/glucagons/vasoactive intestinal peptide (VIP) family. ADCYAP1 has been known to be involved in various biological processes including cell growth, proliferation, and differentiation (18) . One of the main functions of ADCYAP1 is to stimulate adenylate cyclase and subsequently increases the cAMP level in target cells. It also functions as a hypophysiotropic hormone, neurotransmitter, and neuromodulator. In addition, it plays a vital role in paracrine and autocrine regulation of certain types of cells, in the accumulation of estrogen and progesterone, and synthesis of sulfatides, glycolipid, and sphingolipid. Beyond that, many studies in ADCYAP1 have suggested that ADCYAP1 gene expression links to cancer. For example, the ADCYAP1 gene is known to be overexpressed in neuroblastoma (19) and breast cancer (20) . ADCYAP1 has shown neurotrophic actions in human neuroblastoma SH-SY5Y tumor cells (21) and also showed anti-apoptotic effects in a schwannoma cell line (22) . It was Table I . Human cervix tissue samples used in MSP and BSP analyses. -
reported that ADCYAP1 can promote the growth of the BON neuroendocrine tumor cells (23) . On the contrary, it has shown that ADCYAP1 suppresses the proliferation of human κ and Ï light chain-secreting multiple myeloma-derived cells, suggesting that ADCYAP1 is an antitumor agent that directly suppresses myeloma cell growth and indirectly affects tumor cell growth (24) . Taken together, these facts are consistent with a previous report that the ADCYAP1 has both proliferative and anti-proliferative effects on cancer cell growth (25) . Therefore, we examined the effect of promoter methylation on the ADCYAP1 gene expression during the development of cervical cancer. We introduce ADCYAP1 as an effective methylation-based molecular biomarker for the early diagnosis of cervical cancer. Moreover, our further studies suggested that the ADCYAP1 promoter methylation seems to be responsible for the low levels of gene expression in cervical cancer cells.
Materials and methods

Cervical cancer cell lines and human tissue samples.
Eight cervical cancer cell lines were used in this study. C33A, CaSki, HeLa, and SiHa cells were purchased from the American Type Culture Collection (ATCC, USA). The other cell lines, SNU-17, -703, -1160, and -1299 were obtained from the Korean Cell Line Bank (KCLB, Korea). Each cell line was grown in one of the following different media: C33A, HeLa, and SiHa cells in DMEM medium (WelGENE Inc., Korea); CaSki, SNU-703, and SNU-1299 cells in RPMI-1640 medium (Gibco-BRL); SNU-17 and SNU-1160 in AR5 medium (KCLB, Korea). All media were supplemented with 10% fetal bovine serum (Gibco-BRL) and 1% AntibioticAntimycotic (Gibco-BRL). All of these cells were cultured at 37˚C in a humidified atmosphere composed of 95% air and 5% CO 2 . A total of 110 human tissue samples were kindly provided by Dr Chang-Jin Kim at the Soonchunhyang University Hospital (Cheonan, Korea). These tissue samples originated from cervical cancer patients and their information is represented as the histological tumor grade and age in Table I . These tissue samples for CIN diagnosis were prepared by using micro-excision. Patients provided signed informed consent and the procedure of obtaining tissue samples was approved by the Hospital Clinic's Institutional Review Board.
Reverse transcription (RT)-PCR.
Total RNA was extracted from 8 cervical cancer cell lines or human tissue samples using the RNeasy Minikit (Qiagen) following the manufacturer's instructions. For reverse transcription, 1 μg RNA of each sample was subjected to cDNA synthesis using oligo-(dT) primer and RevertAid First Strand cDNA Synthesis Kit (Fermentas, Korea) according to the manufacturer's instruction. PCR amplification was performed using 10 ng cDNA, a primer pair of pRT-ADCYAP1-F and pRT-ADCYAP1-R, and AccuPower PCR PreMix (Bioneer, Korea). The nucleotide sequence of primers and the conditions for gene amplification are shown in Table II . Primers were synthesized by Bioneer. The amplification reaction was carried out using a GeneAmp PCR System 9700 from Applied Biosystems. The amplification products were electrophoresed on a 2% agarose gel stained with ethidium bromide and visualized by using the UV-illuminator or LAS-3000 imaging system.
Methylation-specific PCR (MSP) analysis.
Genomic DNA was extracted from eight cervical cancer cell lines or human tissue samples using DNeasy Blood & Tissue Kit (Qiagen). Bisulfite treatment was performed using 1 μg of genomic DNA at 55˚C for 16 h as following the instruction of EZ DNA Methylation Kit (Zymo Research, CA, USA). Bisulfite-treated DNA was then followed by PCR amplification using two pairs of primer for unmethylated (pMSP-UM-ADCYAP1-F and -R) and methylated (pMSP-M-ADCYAP1-F and -R) DNAs. The nucleotide sequence of each primer and the amplification conditions are shown in Table II . Primers used in this study were synthesized by Bioneer. For all MSP analysis, the PCR mixtures contained 10X reaction buffer, dNTP mixture (1.0 mM), primers (final concentration 10 pmole each per reaction), 1 unit of HotStart ONCOLOGY REPORTS 25: 245-252, 2011 Table II. Oligonucleotide sequences and conditions for PCR analysis. 
a F, forward primer; R, reverse primer; M, methylation-specific primers; U, unmethylated primers.
b All sequences shown in the 5'➝3' direction. Restriction enzymes are represented in italic and lower case letters.
c Conditions are shown as the order of annealing temperature, elongation time, and number of cycles.
prime Taq (Qiagen), and 0.1 μg of bisulfite-treated DNA. The methylation status was inferred by the presence or absence of bands and its density was represented by the thickness of the bands.
Bisulfite sequencing PCR (BSP) analysis. Genomic DNA (1 μg) extracted from each cell line or human tissue samples was bisulfite-treated by using EZ DNA Methylation Kit (Zymo Research). Bisulfite-treated DNA was subjected to PCR reaction using primers of pBSP-ADCYAP1-F and -R (Table II) . Primers were synthesized by Bioneer. The amplified PCR products were cloned into a pBlueScript-SK (+) vector using HindIII and EcoRI restriction enzymes and transformed into DH5· competent cells. Plasmids purified from amphicillin-positive colonies were sequenced using an M13 forward or reverse primer by Solegent (Daejeon, Korea).
Treatment of 5'-aza-2'-deoxycytidine and trichostatin A treatment.
Two cervical cancer cell lines, HeLa and SiHa, were treated with a DNA methyltransferase inhibitor of 5'-aza-2'deoxycytidine (DAC, Sigma) and/or a histone deacetylase inhibitor of trichostain A (TSA, Sigma). Briefly, the cells were plated onto 100-mm plates for 24 h before treatment. HeLa cells were treated with 3.0 μM DAC and/or 0.3 μM TSA for 96 or 48 h, respectively. SiHa cells were treated with 10.0 μM DAC and/or 0.5 μM TSA for 72 or 48 h, respectively.
Statistical analysis. Statistical analyses were carried out with the Statistical Package for the Social Sciences (SPSS) software. Associations of the ADCYAP1 promoter methylation and cervical carcinogenesis were determined using the ¯2 test). Statistical significance was set at P<0.05.
Results and Discussion
Levels of ADCYAP1 gene expression in eight cervical cancer cell lines. The genomic structure of the ADCYAP1 gene is shown in Fig. 1A , which is mapped to chromosome 18p11.32. Nucleotide sequences were obtained from the National Center for Biotechnology Information (http://www.ncbi. nlm.nih.gov/BLAST/). The full-length transcript of the ADCYAP1 gene is shown below the genomic DNA, in which exons are indicated as boxes and numbers. The ADCYAP1 transcript basically contains 4 exons, in which 5'UTR and 3'UTR are indicated by horizontal thick lines. RT-PCR was employed to measure the expression level of the ADCYAP1 gene in eight cervical cancer cell lines (Materials and methods). The positions of pRT-ADCYAP1-F and -R primers are indicated in Fig. 1A . Our result showed that a relatively high level of the ADCYAP1 gene expression was observed only in the C33A cell line, while low levels of the ADCYAP1 gene expression were found in most other cell lines (Fig. 1B) . Moreover, no transcript was detected in the HeLa and SNU-1299 cell lines (Fig. 1B) . Taken together, our result indicates that the ADCYAP1 gene expression is normally repressed in cervical cancer cell lines.
Methylation status of ADCYAP1 promoter in eight cervical cancer cell lines. Putative CpG islands in the ADCYAP1
promoter were predicted using the Methprimer program (http://www.urogene.org//methprimer) (26) with the default setting (%GC >50%, ObsCpG/ExpCpG >0.6) ( Fig. 2A) . High frequency of CpG dinucleotides is found in the ADCYAP1 promoter region (Fig. 2A) . MSP and BSP assays were employed to investigate the methylation level of the ADCYAP1 promoter in eight cervical cancer cell lines (Materials and methods). The MSP assay showed that methylation specific bands were detected in all tested cervical cancer cell lines except for C33A, in which only an unmethylation band was observed (Fig. 2B) . In the case of HeLa, SNU-17, and SNU-1160 cell lines, both methylated and unmethylated PCR products were amplified from the ADCYAP1 promoter (Fig. 2B) . These results suggest that the ADCYAP1 promoter is frequently hypermethylated in most cervical cancer cell lines. The accuracy of the MSP method in detecting methylated DNA was verified by using the BSP assay. We found a general concordant result for the methylation status of the ADCYAP1 promoter in most tested cell lines when compared the MSP and BSP assays. Our data showed that high levels of methylation were exclusively present in most cervical cancer cell lines whereas relatively low levels of methylation were found in the C33A cell line (Fig. 2C) . These results suggest that the ADCYAP1 promoter hypermethylation is a frequent and common event in cervical cancer cell lines. More importantly, our result revealed the inverse relationship between the ADCYAP1 gene expression and promoter methylation level as shown in Figs. 1B and 2 . ). The expression level of the ADCYAP1 gene was measured using RT-PCR. Consistent with our hypothesis, the ADCYAP1 gene expression was reactivated by the drug treatments in HeLa and SiHa cell lines as shown in Fig. 3 . Treatment of either DAC or TSA alone showed no significant effect on ADCYAP1 expression in HeLa cells. However, treatment with DAC and TSA together greatly increased ADCYAP1 expression (Fig. 3) . In the case of SiHa cells, treatment with DAC alone or with DAC and TSA together resulted in a significanct increase in ADCYAP1 expression (Fig. 3) . These data suggest that hypermethylation in the ADCYAP1 promoter is associated with transcriptional silencing of ADCYAP1 gene in HeLa and SiHa cervical cell lines. The ADCYAP1 gene expression was also found to be reactivated by the DAC and TSA treatments in CaSki and SNU-1299 cervical cancer cell lines (data not shown), confirming the negative effect of methylated or deacethylated DNA on the ADCYAP1 gene expression. Taken together, we conclude that the ADCYAP1 promoter hypermethylation is responsible for the low ADCYAP1 gene expression in cervical cancer cells.
Methylation incidence in ADCYAP1 promoter during multistep processes of cervical carcinogenesis. Discovery of the correlation between ADCYAP1 methylation and cervical cancer cell lines suggested the possibility of the same situation in vivo. Therefore, this investigation was extended to human tissue samples from five different stages of cervical carcinogenesis; normal cervix, CIN I, CIN II, CIN III, and invasive carcinoma. We evaluated the methylation level of the ADCYAP1 promoter in a total of 110 cervical tissue samples. Briefly, genomic DNA extracted from tissue samples was modified by sodium bisulfite and then subjected to MSP and BSP analysis (Materials and methods). As shown in Fig. 4A , partial or non-methylated ADCYAP1 promoter was detected in normal tissue samples, whereas a high degree of methylation was observed in CIN III and invasive carcinoma (p=0.00). Methylation density in CIN I and CIN II is clearly higher than those in normal tissues but lower than those in invasive carcinoma samples (p=0.00). This result indicates that methylation in the ADCYAP1 promoter seems to start from CIN I, relatively early stage of multistep carcinogenesis. BSP assay was performed to confirm the result of MSP (Materials and methods). Four or eight clones from each representative sample were sequenced and evaluated for the frequency of ADCYAP1 methylation. None of the normal, CIN I, and CIN II cells exhibited hypermethylation. In contrast, CIN III and invasive carcinoma cells showed high levels of methylation in the ADCYAP1 promoter regions (Fig. 4B) . In general, the BSP result was consistent with that of MSP except for the case of CIN I and CIN II, in which relatively high levels of methylation were found in the ADCYAP1 promoters according to MSP assay. However, our methylation analysis showed a nearly perfect correlation between the ADCYAP1 hypermethylation and cervical carcinogenesis. The level of ADCYAP1 hypermethylation is very low at early stages but starts to increase with the tumor development. This fact suggests that the ADCYAP1 hypermethylation is a tumor-specifc event. It is normally considered that older people have higher levels of methylation compared to younger people, which is consistent with our result. When the ADCYAP1 methylation status and the age of the patients were compared, a significant association between methylation and age was found, in which older patients showed higher levels of DNA methylation in the ADCYAP1 promoter (p=0.00). In conclusion, our analysis evaluating methylation in cervical tissues led to the following conclusions. First, ADCYAP1 methylation is associated with cervical carcinogenesis. Second, this abnormal DNA methylation occurs at the relatively early stages during tumorigenesis of cervical cancer. These results indicate that ADCYAP1 can be used as an effective bio-marker for early detection of cervical cancer. Third, we showed that hypermethylation of the ADCYAP1 promoter is responsible for the transcriptional silencing of this gene in cervical cancer cells. Collectively, our study may contribute to the prevention and optimal treatment of cervical cancer by early detection. In addition, studies on the pattern of the methylation event in this gene may lead to a better understanding of its biological function.
